135 related articles for article (PubMed ID: 18570058)
1. The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer.
Taxel P; Luthra P; Fall PM; Dauser D
Aging Male; 2008 Jun; 11(2):71-5. PubMed ID: 18570058
[TBL] [Abstract][Full Text] [Related]
2. Testosterone loss and estradiol administration modify memory in men.
Beer TM; Bland LB; Bussiere JR; Neiss MB; Wersinger EM; Garzotto M; Ryan CW; Janowsky JS
J Urol; 2006 Jan; 175(1):130-5. PubMed ID: 16406889
[TBL] [Abstract][Full Text] [Related]
3. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy.
Maggio M; Blackford A; Taub D; Carducci M; Ble A; Metter EJ; Braga-Basaria M; Dobs A; Basaria S
J Androl; 2006; 27(6):725-8. PubMed ID: 16775253
[TBL] [Abstract][Full Text] [Related]
4. Associations of long- and short-term air pollution exposure with markers of inflammation and coagulation in a population sample.
Panasevich S; Leander K; Rosenlund M; Ljungman P; Bellander T; de Faire U; Pershagen G; Nyberg F
Occup Environ Med; 2009 Nov; 66(11):747-53. PubMed ID: 19687019
[TBL] [Abstract][Full Text] [Related]
5. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer.
Dockery F; Bulpitt CJ; Agarwal S; Vernon C; Rajkumar C
J Androl; 2009; 30(4):410-5. PubMed ID: 19168445
[TBL] [Abstract][Full Text] [Related]
6. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
[TBL] [Abstract][Full Text] [Related]
7. Bone health in men receiving androgen deprivation therapy for prostate cancer.
Eastham JA
J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
9. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review.
Bylow K; Mohile SG; Stadler WM; Dale W
Cancer; 2007 Dec; 110(12):2604-13. PubMed ID: 17960609
[TBL] [Abstract][Full Text] [Related]
10. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
11. Effects of high dose oestrogen therapy on circulating inflammatory markers.
Wilson R; Spiers A; Ewan J; Johnson P; Jenkins C; Carr S
Maturitas; 2009 Mar; 62(3):281-6. PubMed ID: 19231116
[TBL] [Abstract][Full Text] [Related]
12. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers.
Chu MC; Cushman M; Solomon R; Lobo RA
Am J Obstet Gynecol; 2008 Nov; 199(5):526.e1-7. PubMed ID: 18511016
[TBL] [Abstract][Full Text] [Related]
13. The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer.
Taxel P; Stevens MC; Trahiotis M; Zimmerman J; Kaplan RF
J Am Geriatr Soc; 2004 Feb; 52(2):269-73. PubMed ID: 14728639
[TBL] [Abstract][Full Text] [Related]
14. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
15. The relationship between testosterone and molecular markers of inflammation in older men.
Maggio M; Basaria S; Ceda GP; Ble A; Ling SM; Bandinelli S; Valenti G; Ferrucci L
J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):116-9. PubMed ID: 16760639
[TBL] [Abstract][Full Text] [Related]
16. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.
Hellgren M; Conard J; Norris L; Kluft C
Maturitas; 2009 Mar; 62(3):287-93. PubMed ID: 19268506
[TBL] [Abstract][Full Text] [Related]
18. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ
Menopause; 2008; 15(2):248-55. PubMed ID: 17693902
[TBL] [Abstract][Full Text] [Related]
19. Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema.
Birjmohun RS; Kees Hovingh G; Stroes ES; Hofstra JJ; Dallinga-Thie GM; Meijers JC; Kastelein JJ; Levi M
Clin Ther; 2008 Dec; 30(12):2314-23. PubMed ID: 19167590
[TBL] [Abstract][Full Text] [Related]
20. Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
Eur J Obstet Gynecol Reprod Biol; 2009 Feb; 142(2):139-44. PubMed ID: 19095343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
